Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP2 | P50579 | 6/20 | 0.57 |
| ▸ | METAP1 | P53582 | 1/20 | 0.50 |
| ▸ | ACLY | P53396 | 2/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.48 |
| ▸ | CCR2 | P41597 | 4/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | FABP4 | P15090 | 2/20 | 0.42 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3982846 | 0.84 | METAP2 (0.79) | METAP2METAP1 | |
| SCHEMBL3985161 | 0.83 | METAP2 (0.77) | METAP2METAP1 | |
| SCHEMBL3982715 | 0.82 | METAP2 (0.65) | METAP2METAP1 | |
| SCHEMBL3987902 | 0.81 | METAP2 (0.66) | METAP2METAP1 | |
| SCHEMBL3982809 | 0.80 | METAP2 (0.67) | METAP2METAP1ACLYFABP4FABP5 | |
| SCHEMBL3985482 | 0.78 | METAP2 (0.69) | METAP2METAP1ACLYFABP4 | |
| SCHEMBL3984183 | 0.77 | METAP2 (0.71) | METAP2 | |
| SCHEMBL3982685 | 0.77 | METAP2 (0.67) | METAP2METAP1FABP4FABP5 | |
| SCHEMBL3019459 | 0.73 | KCNH2 (0.52) | ACLYKCNH2CCR2CYP3A4CYP2C9 | |
| SCHEMBL3982656 | 0.73 | METAP2 (1.00) | METAP2METAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040068012-A1 | Sulfonamides having antiangiogenic and anticancer activity | ABBOTT LABORATORIES | 2004-04-08 | — | — | US | claimed |
| US-7491718-B2 | Sulfonamides having antiangiogenic and anticancer activity | ABBOTT LABORATORIES (US) | 2009-02-17 | — | — | US | disclosed |
| EP-1549613-A1 | SULFONAMIDES HAVING ANTIANGIOGENIC AND ANTICANCER ACTIVITY | Abbott Laboratories (US) | 2005-07-06 | — | — | EP | disclosed |
| US-20040167128-A1 | Sulfonamides having antiangiogenic and anticancer activity | ABBVIE INC. | 2004-08-26 | — | — | US | disclosed |
| US-20040157836-A1 | Sulfonamides having antiangiogenic and anticancer activity | ABBOTT LABORATORIES | 2004-08-12 | — | — | US | disclosed |
| WO-2004033419-A1 | SULFONAMIDES HAVING ANTIANGIOGENIC AND ANTICANCER ACTIVITY | ABBOTT LABORATORIES (US) | 2004-04-22 | — | — | WO | disclosed |
| US-20040068012-A1 | Sulfonamides having antiangiogenic and anticancer activity | ABBOTT LABORATORIES | 2004-04-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040167128-A1 | Sulfonamides having antiangiogenic and anticancer activity | METAP2, METAP1, DNPEP | METAP2 1/4885METAP1 2/4885ACLY 2986/4885 |
| US-20040068012-A1 | Sulfonamides having antiangiogenic and anticancer activity | METAP2, METAP1, DNPEP | METAP2 1/4885METAP1 2/4885ACLY 2986/4885 |
| US-20040157836-A1 | Sulfonamides having antiangiogenic and anticancer activity | METAP2, METAP1, DNPEP | METAP2 1/4885METAP1 2/4885ACLY 2986/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.